Specturi Device - Feasibility Study
Specturi Device Study
Sponsor: Capturin Distribution B.V.
Listed as NCT03105557, this observational or N/A phase trial focuses on Rickets and remains completed. Sponsored by Capturin Distribution B.V., it has been updated 13 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Feb 2026 — Present [monthly]
Completed
Status: Unknown → Completed
-
Mar 2025 — Feb 2026 [monthly]
Unknown
Status: Recruiting → Unknown
-
Sep 2024 — Mar 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Mar 2023 — Jul 2024 [monthly]
Recruiting
▶ Show 8 earlier versions
-
Sep 2021 — Mar 2023 [monthly]
Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting
-
May 2020 — Jan 2021 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
Aug 2019 — May 2020 [monthly]
Not Yet Recruiting
-
Apr 2019 — Aug 2019 [monthly]
Not Yet Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Not Yet Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
May 2017 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Capturin Distribution B.V.
- Fonds NutsOhra
- FrieslandCampina
- Hertog Hendrik BV
- Radboud University Medical Center
- Rijnstate Hospital
- Scint B.V.
- University of Twente
For direct contact, visit the study record on ClinicalTrials.gov .